ReviewAging2012
Recent discoveries in the cycling, growing and aging of the p53 field.
Review in Aging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Ferroptosis: A New Regulatory Mechanism in Osteoporosis.Oxidative medicine and cellular longevity · 2022Review
- Metformin-induced activation of AMPK inhibits the proliferation and migration of human aortic smooth muscle cells through upregulation of p53 and IFI16.International journal of molecular medicine · 2018Article
- Tumoricidal activities of pterostilbene depend upon destabilizing the MTA1-NuRD complex and enhancing P53 acetylation in hepatocellular carcinoma.Experimental and therapeutic medicine · 2017Article
- ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels.Cell cycle (Georgetown, Tex.) · 2015Article
- Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Oncotarget · 2014Article
- Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Article
- Article
- Geroconversion: irreversible step to cellular senescence.Cell cycle (Georgetown, Tex.) · 2014Review
- Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers.Oncotarget · 2013Article
- GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation.Cell cycle (Georgetown, Tex.) · 2013Article
- p53 regulates the transcription of the anti-inflammatory molecule developmental endothelial locus-1 (Del-1).Oncotarget · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The P53 gene and it product p53 protein is the most studied tumor suppressor, which was considered as oncogene for two decades until 1990. More than 60 thousand papers on the topic of p53 has been abstracted in Pubmed. What yet could be discovered about its role in cell death, growth arrest and apoptosis, as well as a mediator of the therapeutic effect of anticancer drugs. Still during recent few years even more amazing discoveries have been done. Here we review such topics as suppression of epigenetic silencing of a large number of non-coding RNAs, role of p53 in suppression of the senescence phenotype, inhibition of oncogenic metabolism, protection of normal cells from chemotherapy and even tumor suppression without apoptosis and cell cycle arrest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.